Advice

following a full submission:

durvalumab (Imfinzi®) is not recommended for use within NHSScotland.

Indication under review: In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements.

In a randomised, double-blind, phase III study, the addition of neoadjuvant and adjuvant durvalumab compared with the addition of placebo to neoadjuvant chemotherapy significantly improved complete pathological response and event-free survival in patients with resectable NSCLC.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Medicine details

Medicine name:
durvalumab (Imfinzi)
SMC ID:
SMC2677
Indication:

In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node-positive) NSCLC and no known EGFR mutations or ALK rearrangements.

Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published
09 December 2024